Akari Therapeutics (AKTX) Change in Accured Expenses (2014 - 2026)
Akari Therapeutics (AKTX) posted quarterly Change in Accured Expenses of $931000.0 for Q1 2026, up 92.75% year-on-year from $483000.0 in Q1 2025, and up 611.54% on a QoQ basis from -$182000.0 in Q4 2025.
Akari Therapeutics (AKTX) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Change in Accured Expenses for 9 consecutive years, with $931000.0 the latest figure, recorded in Q1 2026.
- Quarterly Change in Accured Expenses rose 92.75% year-over-year to $931000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$550000.0 (down 112.95% YoY) and the FY2025 annual result came in at -$998000.0, down 119.11% from the prior year.
- Change in Accured Expenses rose to $931000.0 in Q1 2026 per AKTX's latest filing, from -$182000.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for AKTX reached as high as $1.5 million in Q2 2024 and fell as low as -$704000.0 in Q3 2025.
- A 4-year average of $324615.4 and a median of -$100000.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses jumped 1441.0% — and 2025, when it sank 175.37%.
- Year by year, Change in Accured Expenses stood at -$100000.0 in 2023, then soared by 1441.0% to $1.3 million in 2024, then tumbled by 113.57% to -$182000.0 in 2025, then soared by 611.54% to $931000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $931000.0, -$182000.0, and -$704000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | -16.74 Mn |
| 10 | Alnylam Pharmaceuticals | 37.44 Bn | 34.43 Bn | 959.66 Mn | -176.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 931,000.00 |
| Mar 31, 2026 | 931,000.00 |
| Dec 31, 2025 | -182,000.00 |
| Dec 31, 2025 | -182,000.00 |
| Sep 30, 2025 | -704,000.00 |
| Sep 30, 2025 | -704,000.00 |
| Jun 30, 2025 | -595,000.00 |
| Jun 30, 2025 | -595,000.00 |
| Mar 31, 2025 | 483,000.00 |
| Mar 31, 2025 | 483,000.00 |
| Dec 31, 2024 | 1.34 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 934,000.00 |
| Sep 30, 2024 | 934,000.00 |
| Jun 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | -100,000.00 |
| Dec 31, 2023 | -100,000.00 |